Press Release: PatientCraft Publishes Results of 340B Stakeholders Survey
Press Release: PatientCraft Publishes Results of 340B Stakeholders Survey [...]
HIT Think: Why data will grow in importance for drug pricing
The 340B drug pricing program, enacted in 1992, provides discounts on outpatient drugs to safety-net providers (called 340B covered entities) who meet certain qualifications. Covered entities use the savings from the program to stretch scarce federal resources and invest in patient care.
PatientCraft Announces Holly Russo as President and CEO
PatientCraft, a healthcare consulting firm specializing in 340B program optimization, audit readiness and compliance, today announced the addition of industry expert, Holly Russo, RN, MSN, MSECS, as its new president and CEO. With the appointment of Russo, the company is also moving its corporate office from Dallas to El Paso.
Accountable Care Organizations Should Partner with 340B Covered Entities
There is a great opportunity for Accountable Care Organizations (ACOs) to take advantage of and partner with covered entities that are eligible for 340B drug pricing.
The Future of Payment Policy
Today we face some of the most significant changes in payment policy, and an increased focus on quality of care to outcome and reimbursement.
GAO’s Flawed Analysis Paints Wrong 340B Picture
Last month, the Government Accountability Office (GAO) issued a critical report on the 340B program. GAO interviewed 61 stakeholders in the program about their ability to generate savings and distribute drugs. GAO also examined the adequacy of federal oversight of the program.